# KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

> **NCT04165798** · — · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1065 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DIAGNOSTIC_TEST:** Tumor Imaging
- **PROCEDURE:** Tumor Tissue Collection
- **PROCEDURE:** Blood Sample Collection

## Key facts

- **NCT ID:** NCT04165798
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-19
- **Primary completion:** 2032-02-13
- **Final completion:** 2032-02-13
- **Target enrollment:** 1065 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165798, "KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)". Retrieved via AI Analytics 2026-08-14 from https://api.ai-analytics.org/clinical/NCT04165798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*